A Retrospective Study of Prognostic Factors and Survival of Breast Cancer Patients with Brain Metastesis

Study Purpose

The aim of the study is to to describe the pattern of BM in breast cancer patients, assess the prognostic significance of patient related-factors and to evaluate the efficacy of various treatment modalities. clinicopathological factors and prognostic factors that affect the occurrence of brain metastases and which factors affect the survival after the occurrence of brain metastases remain to be identified . This may help identify patients at high risk for brain metastases and patients with poor prognosis after brain metastases, thus providing them with some preventive or therapeutic measures.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Observational
Eligible Ages	18 Years and Over
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- -Age >18.

- Histological proven breast cancer.

- Radiological documentation of BM by computed tomography (CT) OR magnetic resonance imaging (MRI) - Patients who had been followed up for at least 6 months.

Exclusion Criteria:

- -Not histologically proven Breast cancer.

- Patient without full medical data.

- Those with previous or concurrent diagnosis of second primary malignancy.

- Patients with leptomeningeal or dural metastases without co-existent parenchymal metastatic lesions

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT06723132
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Assiut University
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	N/A
Principal Investigator Affiliation	N/A
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Not yet recruiting
Countries
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Breast Cancer

Additional Details

Breast cancer (BC) has become the malignancy with the highest morbidity rate in women. Despite significant advances in the diagnosis and treatment of breast cancer, metastasis is still an important factor that seriously affects patients' quality of life and prognosis. It has been reported that distant metastases have been found at the initial diagnosis of breast cancer in about 6-10% of patients The bones, lungs, liver and brain are the four most common distant metastatic sites of breast cancer Compared with bone metastases and visceral metastases, patients with brain metastases have significantly worse prognosis The median time from diagnosis of breast cancer to CNS metastasis has been reported to be 33 month The survival of these patients may be affected by factors including molecular subtypes, performance status, ressectability of BM and visceral metastasis burden. When detected, its treatment is usually difficult and unfortunately has reverse effects on life expectancy Multi-disciplinary therapy (MDT) is the first choice for the treatment of brain metastases in breast cancer MDT for breast cancer brain metastasis includes surgery, whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), chemotherapy, endocrine therapy, targeted therapy, etc. For patients with multiple brain metastases and neurological symptoms, WBRT combined with palliative care is the preferred option In general, patients with brain metastases of 3 or less were recommended to receive surgical resection. Patients with 4 to 5 brain metastases but less 3cm in diameter can undergo SRS .

Arms & Interventions

Arms

: breast cancer

breast cancer patients with -Radiological documentation of BM by computed tomography (CT) OR magnetic resonance imaging (MRI)

Interventions

Contact Information

This trial has no sites locations listed at this time. If you are interested in learning more, you can contact the trial's primary contact:

Huda Thabet Mohamed, resident doctor

[email protected]

+201152476153

For additional contact information, you can also visit the trial on clinicaltrials.gov.

Clinical Trial Finder